Since the end of 2019 and the beginning of 2020, I have been looking at ADCs, and I have discussed with many experts in the field, leading to many misunderstandings, and my understanding has been continuously refreshed. Many articles about ADCs exist, but many of them contain misunderstandings. Now, there are more successful and failed … Read more
Antibody-drug conjugates (ADCs) have become a popular avenue for cancer treatment in recent years. They typically consist of monoclonal antibodies (mAbs) covalently linked to cytotoxic drugs (payloads) through chemically synthesized linkers. ADCs combine the advantages of high specificity targeting and effective killing action, achieving precise and efficient elimination of cancer cells. Figure 1. Structure and … Read more
Introduction Antibody-drug conjugates (ADCs) are formed by linking monoclonal antibodies that target specific antigens with small molecule cytotoxic drugs through linkers, combining the powerful killing effect of traditional small molecule chemotherapy with the tumor targeting ability of antibody drugs.ADCs consist of three main components: the antibody responsible for selectively recognizing cancer cell surface antigens, the … Read more
Author | Little Fish Periodically, major pharmaceutical media and authoritative journals summarize the development of ADCs. Recently, a review on ADCs published by the internationally renowned journal ACS caught our attention. As a member of CAS (American Chemical Society), Janet M. Sasso’s team innovatively used patents and articles related to ADCs within CAS as data … Read more
Known as magic bullets, ADCs have been highly praised in recent years. The design concept of these drugs is clear: to utilize the high specificity of antigen-antibody binding to selectively deliver toxins to antigen-positive cells, thereby selectively killing target cells and reducing damage to normal cells. However, like other drugs, the actual performance of ADCs … Read more
Introduction Antibody-drug conjugates(ADC) are formed by linking monoclonal antibodies targeting specific antigens with small molecule cytotoxic drugs through linkers, combining the powerful killing effect of traditional small molecule chemotherapy with the tumor targeting ability of antibody drugs. ADC consists of three main components: the antibody responsible for selectively recognizing cancer cell surface antigens, the drug … Read more
The cancer-associated fibroblast (CAF) barrier in pancreatic ductal adenocarcinoma (PDAC) significantly restricts clinical prognosis. The main obstacles in PDAC treatment include limited immune cell and drug penetration, as well as an immunosuppressive microenvironment. Based on this, Yongjun Liu and Na Zhang from Shandong University reported a “shooting fish in a barrel” strategy by preparing a … Read more
Recently, Associate Professor Zhang Wenli’s team at China Pharmaceutical University published a review titled “The Janus of Protein Corona on Nanoparticles for Tumor Targeting, Immunotherapy and Diagnosis” in Journal of Controlled Release, Volume 345, 2022, and it was selected as the Inside Back Cover article of that issue.. Figure 1. The dual-edged effect of protein … Read more
Sonodynamic therapy (SDT) is a non-invasive treatment method based on reactive oxygen species (ROS) that interacts with ultrasound (US) activated sonosensitizers and surrounding oxygen and water molecules to produce highly cytotoxic ROS and induce apoptosis. Due to its ability to penetrate deep tissues while causing minimal damage to normal cells, it has significant potential in … Read more
iNature Immunotherapy shows great promise in cancer treatment. However, the highly immunosuppressive nature of solid tumors limits its effectiveness. On October 15, 2024, the research paper titled “Zinc-Nickel Bimetallic Hydroxide Nanosheets Activate the Paraptosis–Pyroptosis Positive Feedback Cycle for Enhanced Tumor Immunotherapy” was published online in ACS Nano by Cheng Liang from Soochow University and Hou … Read more